A case for newborn screening for pyridoxine-dependent epilepsy

Area of Science:

• Biochemistry
• Genetics
• Neurology

Background:

• Pyridoxine-dependent epilepsy (PDE-ALDH7A1), caused by ALDH7A1 mutations, is a treatable developmental and epileptic encephalopathy.
• Pyridoxine therapy offers significant seizure control, but delayed diagnosis can be fatal.
• Current treatments, while effective for seizures, do not fully prevent intellectual and developmental delays.

Purpose of the Study:

• To advocate for newborn screening for PDE-ALDH7A1.
• To highlight the benefits of early diagnosis and treatment for mortality and cognitive outcomes.
• To discuss the potential of newly identified biomarkers for screening.

Main Methods:

• Review of clinical data and treatment outcomes for PDE-ALDH7A1.
• Evaluation of newly identified biomarkers for newborn screening feasibility.
• Assessment of criteria for implementing newborn screening programs.

Main Results:

• PDE-ALDH7A1 meets established criteria for newborn screening.
• Neonatal diagnosis and treatment can significantly reduce mortality and improve cognitive development.
• Adjunct lysine reduction therapies show developmental benefits if initiated early.

Conclusions:

• Newborn screening for PDE-ALDH7A1 is warranted to reduce mortality and improve developmental trajectories.
• Timely diagnosis and initiation of pyridoxine and lysine reduction therapies are critical for optimal patient outcomes.
• Advances in biomarker identification facilitate the implementation of newborn screening for this condition.